The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4 þ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients were included with following diagnoses: acute myeloid leukemia 42, acute lymphoblastic leukemia 5, chronic myeloid leukemia 15, non-Hodgkin's lymphoma 5 and high-risk myelodysplastic syndrome 2. The peripheral lymphocyte subset counts (CD3 þ T cells, CD3
þ B cells, and CD56 þ natural killer cells) were measured at 3, 6 and 12 months. The CD4
þ helper T-cell reconstitution at 3 months was strongly correlated with OS (Po0.0001), NRM (P ¼ 0.0007), and opportunistic infections (P ¼ 0.0108) at the cutoff value of 200 Â 10 6 /l CD4 þ helper T cells. Rapid CD4 þ helper T-cell recovery was also associated with a higher CD4
þ helper T-cell transplant dose (P ¼ 0.006) and donor type (Po0.001). An early CD4
þ helper T-cell recovery at 3 months correlated with a subsequent faster helper T-cell recovery until 12 months, yet not with B-cell recovery. In a multivariate analysis, rapid recovery of CD4 þ helper T cells at 3 months was a favorable prognostic factor together with higher CD34 þ cell transplant dose in terms of OS (P ¼ 0.001) and NRM
Introduction
Reconstitution of the immune system has recently been highlighted as an important issue to achieve successful long-term outcome after allogeneic stem cell transplantation (SCT), as severe or prolonged immune deficiency during the post transplant period invariably resulted in a prolonged susceptibility to infection. [1] [2] [3] [4] [5] A delayed immune reconstitution after allogeneic SCT is mainly derived from the dysfunction of the thymus, the main organ of T-cell maturation. 5 The CD4 þ T-cell reconstitution occurs through an early peripheral expansion of graft mature memory T cells (thymic-independent pathway) 6, 7 followed by a central output of naı¨ve thymic emigrants (thymicdependent pathway), where normalization can take up to 1 year. 8, 9 Thus, quantitative CD4 þ helper T-cell counts within 1-year post transplant can reflect the thymicindependent peripheral expansion of CD4 þ helper T cells, mostly with a memory T-cell phenotype. These CD4 þ helper T cells have a central function in the generation, maintenance and regulation of both humoral-and cellmediated immunity. 10, 11 In a previous study, accelerated CD4 þ T-cell recovery was found to decrease the infection risk after allogeneic SCT. 2 To evaluate the degree of immune reconstitution during the post transplant period, several kinds of complex techniques, such as a T-cell receptor rearrangement excision circle (TREC), CD3R spectratyping, or enzymelinked immunosorbent assay (ELISA)/ELISPOT, have been used for research purposes. 1 However, applying these techniques in a clinical setting is more restricted due to their complexity and high cost. As such, quantitative measurement of lymphocyte subsets using a flow cytometric method has been widely applied in the transplantation field. From experience with acquired immunodeficiency syndrome, the prognostic implications of a quantitative CD4 þ helper T-cell defect after allogeneic SCT include infections and nonrelapse mortality (NRM). In human immunodeficiency virus (HIV)-infected patients, when the CD4 þ helper T-cell count drops below 200 Â 10 6 /l, the risk of infection substantially increases, requiring prophylaxis or vaccination against such infections, 12,13 yet such data defining a delayed immune reconstitution is scarce in a SCT setting. Accordingly, the current study attempted to evaluate (1) the role of peripheral lymphocyte recovery, especially CD4 þ helper T-cell recovery, in predicting transplant outcomes, including overall survival (OS), NRM, and infections, and (2) the impact of a rapid CD4 þ helper T-cell recovery on the subsequent immune reconstitution following 3 months post transplant.
Materials and methods

Patient characteristics and transplantation procedures
A total of 69 patients who received an allogeneic SCT from histocompatibility leukocyte antigen (HLA)-matched sibling (n ¼ 47), unrelated (n ¼ 19), or partially mismatched family donors (n ¼ 3) at Kyungpook National University Hospital between December 1996 and 2004 with available data on peripheral counts of their lymphocyte subsets at 3 months were enrolled in the current study. The characteristics of the patients were as follows: the median age was 34 years (range 16-58 years) with a male to female ratio of 67:33 (n ¼ 46:23). The enrolled diseases included acute myeloid leukemia (n ¼ 42, 61%), acute lymphoblastic leukemia (n ¼ 5, 7%), chronic myeloid leukemia (n ¼ 15, 22%), non-Hodgkin's lymphoma (n ¼ 5, 7%), and high-risk myelodysplastic syndrome (MDS, n ¼ 2, 3%; including RAEB-I, -II, and CMML) with 44 and 25 patients exhibiting a standard (64%) and advanced (38%) disease status, respectively. Severe aplastic anemia or low-risk MDS were excluded from the current study. The transplant procedures were conducted as previously described. 14, 15 Briefly, the conditioning regimens for the allogeneic recipients were busulfan/cytoxan (BuCy; n ¼ 47) or fludarabine-based reduced intensity conditioning (n ¼ 22). The fludarabine-based regimen was as follows: (1) fludarabine, busulfan and cyclophosphamide (n ¼ 12), (2) fludarabine and busulfan (n ¼ 6), (3) fludarabine, idarubicin and cytarabine (n ¼ 4). Aphareses procedures were performed on 47 patients (68%) with sibling (n ¼ 44) or partially mismatched family donors (n ¼ 3), as previously described, 16 ., Seoul, Korea) were added to 100 ml of cells isolated from ethylenediaminetetra-acetic acid anticoagulated blood using a lysis buffer, followed by incubation for 15 min at room temperature. The lymphocytes were then gated based on their log-side scatter and forward scatter characteristics. The absolute count for each cellular subset was calculated as the product of the absolute WBC count, lymphocyte differential percentage, and cellular subset percentage, as evaluated by flow cytometry. Serial measurements of the peripheral lymphoid cells using flow cytometry were performed 3, 6 and 12 months after allogeneic SCT.
Definitions
The day of the stem cell infusion was defined as day 0. Acute and chronic GVHD were diagnosed and graded using established criteria. 18, 19 Overall survival was defined as the time from transplantation until death from any cause. Non-relapse mortality was defined as death not related to disease recurrence or progression. The cumulative incidence of relapse was defined as the time from transplantation until disease progression. The day of an infectious event was defined as the day when the clinical symptom or sign of infection was first reported. The causative organisms were identified by microbiologic or histological methods. cytomegalovirus reactivation was excluded as a cause of viral infection in the current study. /l were also calculated after 3, 6 and 12 months.
Statistical analysis
A multiple linear regression analysis was used to determine possible factors influencing the CD4 þ helper T-cell recovery. The absolute number of CD4 þ helper T cells at 3 months was used as a dependent variable, while the patient's and donor's age and transplant dose of
þ B cells, and CD56 þ NK cells were included as continuous explanatory variables, and the donor type (HLA-identical sibling vs others) included as a categorical explanatory variable.
The estimates of OS or cumulative incidence of NRM, relapse, and infection were calculated using the method of Kaplan and Meier. The differences between OS, NRM, the probability of relapse, and infection were compared using a log-rank test. For the multivariate survival analyses, a logminus-log plot was first checked to assess the effectiveness of fitting a time-dependent Cox's proportional hazard model using chronic GVHD as a time-dependent covariate. However, when this was not found to be appropriate, Cox's proportional hazard model was used instead to define the prognostic factors for OS, NRM, and the probability of relapse based on a backward conditional procedure until the P-value for the likelihood ratio test was 40.05. The following variables were included in the analyses: CD4 /kg), source of stem cells (PBSC vs BM), donor (HLA-identical sibling vs others), acute GVHD (grade 0-2 vs 3, 4), any grade of chronic GVHD since 3 months and extensive chronic GVHD. The hazard ratio (HR) and 95% CI were also estimated. A cutoff P-value of 0.05 was adopted for all the statistical analyses, and the statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA).
Results
Immune reconstitution after allogeneic stem cell transplantation For all 69 patients, the immune reconstitution pattern is shown in Figure 1 for each lymphocyte subset. In summarizing, the CD19 þ B-cell reconstitution was slow: only 39% of the patients recovered CD19 þ B-cell counts above 50 Â 10 6 /l at 3 months, while 45% and up to 70% recovered such counts after 6 months and 1 year, respectively. Conversely, rapid CD56 þ NK cell recovery was noted: 87% of the patients recovered CD56 þ NK cell counts above 100 Â 10 6 /l at 3 months, then maintained a plateau.
As regards the T-cell recovery, an inverted CD4 þ /CD8 þ ratio was continuously observed during the 1st year, where the CD4 þ helper and CD8 þ cytotoxic T-cell counts showed a rising pattern. Seventy-five percent of the patients recovered CD4 þ helper T-cell counts above 200 Â 10 6 /l at 3 months, 79% after 6 months, and up to 80% after 1 year, whereas for the CD8 þ Tc, 67, 72 and 76% of the patients exhibited CD8 þ cytotoxic T cell counts above 200 Â 10 6 /l after 3, 6 and 12 months, respectively.
Patient characteristics and transplantation procedures
The patient characteristics and transplantation procedures are summarized in 
Transplantation outcomes according to CD4
þ helper T-cell reconstitution at 3 months post transplant The transplant outcomes are summarized in Table 2 . Briefly, with a median follow-up duration of 627 days (range 118-2227 days), the frequency of acute and chronic GVHD was 49 cases (71%) and 56 cases (81%), respectively. Among the total 69 cases, 29 patients (42%) died, among which 18 patients for NRM (26%) and 11 patients for progressive disease (16%). The 2-year OS rate was estimated as 56.876.4%, while the 2-year cumulative incidence of NRM and relapse was estimated as 30.676.4 and 38.1%76.7, respectively.
When comparing the transplant outcomes according to the CD4 þ helper T-cell reconstitution at 3 months (Figure 2 ), the patients with a rapid reconstitution of CD4 However, no difference in the probability of relapse after 1 year was noted according to the CD4 þ helper T-cell reconstitution at 3 months (P ¼ 0.1237). For the incidence of infection according to the CD4 þ helper T-cell reconstitution at 3 months, significant differences were found in favor of the rapid reconstitution of CD4 þ helper T cells (P ¼ 0.0108). In addition, the patients with a rapid reconstitution of CD4 þ helper T cells showed a lower incidence of bacterial (P ¼ 0.0016), viral (P ¼ 0.0542) and fungal infections (P ¼ 0.0461). Interestingly, a significant association between a rapid reconstitution of CD4 þ helper T cells and a lower incidence of extensive chronic GVHD was also noted (P ¼ 0.0092).
Multivariate survival analysis
In the multivariate survival analysis using Cox's proportional hazard model, a rapid reconstitution of CD4 þ helper T cells was identified as a favorable risk factor for OS (P ¼ 0.001, HR 3.653 (1.683-7.933)), together with a higher CD34 þ cell transplant dose (P ¼ 0.033, HR 2.539) ( Table 3A) . As regards NRM, a rapid reconstitution of CD4 þ helper T cells was also found to be associated with a lower NRM than a delayed reconstitution (P ¼ 0.029, 3.758 (1.146-12.325)), together with a higher CD34 þ cell transplant dose (P ¼ 0.001, HR 15.973) and the development of extensive chronic GVHD (P ¼ 0.029, HR 4.098). However, a rapid reconstitution of CD4 þ helper T cells at 3 months was not associated with a lower risk of relapse in the multivariate analysis. Meanwhile, an additional multivariate survival analysis confined to PBSC recipients (Table 3B) revealed a similar trend, where a rapid reconstitution of CD4 þ helper T cells was independently associated with an improved OS.
Linear regression analysis
To investigate which composition of transplanted cells affected the recovery kinetics of CD4 þ helper T cells at 3 months, a linear regression analysis was performed using the absolute number of peripheral CD4 þ helper T-cell counts at 3 months as a dependent variable, while factors relevant to the lymphocyte immune reconstitution were chosen as explanatory variables (see Statistical analysis). Two factors were identified as having a significant effect on the CD4
þ helper T-cell reconstitution at 3 months: the 
-cells (a), B-cells (b), helper T-cells (c), cytotoxic T cells (d) or NK cells (e) for all patients after allogeneic stem cell transplantation (SCT).
Rapid helper T-cell recovery after allogeneic SCT DH Kim et al donor type (Po0.001) and CD4 þ helper T-cell transplant dose (P ¼ 0.006). No effect was seen in relation to other cell compositions or the recipient/donor age.
Influence of early CD4
þ helper T-cell recovery on lymphocyte reconstitution within 1 year after allogeneic transplantation To investigate the influence of a rapid recovery of CD4 þ helper T cells at 3 months on the subsequent lymphoid immune reconstitution of each subset between 3 months and 1 year after SCT, Student's t-tests were performed using an absolute count of each subset at 3, 6 and 12 months between the patients with a rapid and delayed recovery of CD4 þ helper T cells (Table 4) . Irrespective of the lymphocyte subset type, the absolute cell counts at 3 months correlated to the CD4 þ helper T-cell reconstitution (Po0.001 for CD3 þ T cells, Po0.001 for CD4 þ helper T cells, Po0.001 for CD8
þ Tc, P ¼ 0.019 for CD19 þ B cells, and P ¼ 0.007 for CD56 þ NK cells). In addition, the patients with a rapid CD4 þ helper T-cell reconstitution at 3 months exhibited higher CD4 þ helper T-cell counts at 6 months than the patients with a delayed CD4 þ helper T-cell recovery (455740 vs 230741 Â 10 6 /l; P ¼ 0.005).
Thereafter, to confirm the difference in the serial reconstitution pattern for each subset, repeated measurements of the general linear model were performed for each subset. As shown in Figure 3 , a rapid recovery of CD4 þ helper T cells was strongly associated with a subsequent CD4 þ helper T-cell reconstitution between 3 months and 1 year post transplant (P ¼ 0.018), and marginally correlated with a CD3 þ T-cell recovery between 3 months and 1 year (P ¼ 0.091), although not with the other cell subsets.
Discussion
The current study examined the impact of a rapid CD4 The immune reconstitution depends on the generation of new T cells from hematopoietic stem cell, while the transfer of committed progenitors or mature donor-derived T cells facilitates short-term immune functions. 9, 20 In previous studies, thymus-dependent T-cell regeneration (thymicdependent pathway), 6 ,7 bearing a naive phenotype, was delayed up to 1-year post transplant, while extrathymically expanded T cells (thymic-independent pathway), 8, 9 bearing a memory phenotype, was rapidly recovered during the early post transplant period. 4, 21, 22 In addition, prior investigations have suggested that the expansion of T cells likely occurs through the proliferation of memory cells, and that the extrathymic differentiation of stem cells also contributes to the formation of the peripheral blood population. 23, 24 Therefore, based on these observations, a quantitative CD4 þ helper T-cell count would appear to reflect the thymic-independent peripheral expansion of CD4 þ helper T cells within 1-year post transplant, rather than the thymic-dependent central output of naive T cells.
Consequently, the current study analyzed the quantitative value of CD4 þ helper T cells, even though their immediate functional capacity was believed to be limited, after allogeneic SCT. Also, based on experience with HIV infections, a quantitative CD4 þ helper T-cell defect after allogeneic SCT was expected to have implications on the risk of infection and NRM. As such, the cutoff value for CD4 þ helper T cells of 200 Â 10 6 /l used in the present study was derived from experience with HIV infections, as below this level the risk of infections is substantially increased in HIV infected patients, requiring prophylaxis or vaccination against such infections.
12,13 As a result, the data from the current study revealed higher incidences of all kinds of bacterial, viral, and fungal infections among the patients with a lower CD4 þ helper T-cell count at 3 months than those with a higher count. Similarly, in a previous study by Storek et al., 2 an accelerated CD4 þ T-cell recovery was found to decrease the infection risk after allogeneic SCT, while an increased risk of infectious morbidity was found with a low CD4 þ T-cell count. Consequently, the present study suggests that CD4 þ helper T-cell dysfunction and quantitative CD4
þ helper T-cell defects both have a predictive value in the development of infections or NRM, thereby influencing the transplant outcomes. Yet, further study is required to reach a clear conclusion on the association of a quantitative CD4 þ helper T-cell analysis with immune reconstitution after allogeneic SCT.
Similar to previous investigations, 25, 26 an early CD4 þ helper T-cell reconstitution was found to be affected by the CD4 þ T-cell transplant dose. In addition, in the present study, the subsequent immune reconstitution of CD4 þ helper T cells between 3 months and 1 year was found to be dependent on the recovery of CD4 þ helper T cells at 3 months. Possible explanations are that: (1) the thymicindependent peripheral expansion of T cells was maintained at least up to 6 months post transplant, and (2) no factors damaging the thymic regeneration, such as chronic GVHD, occurred frequently in the patients with a rapid recovery of CD4 þ helper T cells, which was supported by the finding of a low incidence of extensive chronic GVHD in the patients with higher CD4 þ helper T-cell counts at 3 months (Figure 2h ). 
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Over the past decade, a variety of techniques have been used to characterize donor-derived T-cell reconstitution after allogeneic SCT, such as TRECs, CD3R spectratyping and ELISA/ELISPOT, 1 all of which are relatively complex and expensive functional assays, making them impossible to perform routinely in a clinical setting. Furthermore, none of these assays have a cutoff value to stratify patients according to their risk of infection or NRM. Therefore, a quantitative T-cell analysis using a flow-cytometric method, which is already widely applied in the transplantation field, 1, 27 would seem to be useful for clinical practice even though Table 3 Multivariate survival analysis of prognostic factors for overall survival and cumulative incidence of non-relapse mortality or relapse in all patients (A; n ¼ 69) and PBSC recipients (B; n ¼ 47) a For the analysis, the CD4 + helper T-cell count at 3 months (X200 Â 10 6 /l vs o200 Â 10 6 /l), the CD19 + B-cell count at 3 months (X50 Â 10 6 /l vs o50 Â 10 6 / l), disease status (standard vs advanced risk), CD34
OS
+ transplant dose (6 Â 10 6 /kg), source of stem cells (PBSCs vs BM), donor (HLA-identical sibling vs others), acute GVHD (grade 0-2 vs 3, 4), any grade of chronic GVHD since 3 months and extensive chronic GVHD were all included. b For the analysis, the CD4 + helper T-cell count at 3 months (X200 Â 10 6 /l vs o200 Â 10 6 /l), the CD19 + B-cell count at 3 months (X50 Â 10 6 /l vs o50 Â 10 6 / l), disease status (standard vs advanced risk), CD34
+ transplant dose (6 Â 10 6 /Kg), acute GVHD (grade 0-2 vs 3,4), any grade of chronic GVHD since 3 months and extensive chronic GVHD were all included. Table 4 Helper T-cell counts at 3 months and its influence on subsequent immune reconstitution until 12 months it is not an absolute standard for evaluating the immune recovery of a patient.
In conclusion, the present findings suggest that the rapid recovery of a CD4 þ T-cell count above 200 Â 10 6 /l at 3 months would seem to reflect a faster immune reconstitution and predict a successful transplant outcome after allogeneic SCT. Nonetheless, further study is strongly warranted to reach a final conclusion on the predictive role of a quantitative evaluation of the immune reconstitution as regards transplant outcomes after allogeneic SCT.
